Table 3.
Clinico-pathological parameters of high grade, invasive bladder tumors in relation to ST6GAL1 protein expression
ST6GAL1 IRS b | ||||||
---|---|---|---|---|---|---|
n a | low (IRS 0–3) | high (IRS 4–12) | P-value c | Spearmanrs | ||
Parameter: | ||||||
Age at diagnosis | ||||||
≤69 years | 27 | 10 | 17 | 0.987 | 0.002 | |
>69 years | 38 | 14 | 24 | |||
Gender | ||||||
Female | 21 | 8 | 13 | 0.894 | 0.017 | |
Male | 44 | 16 | 28 | |||
Histological tumor graded | ||||||
G2 | 7 | 4 | 3 | 0.247 | 0.146 | |
G3 | 58 | 20 | 38 | |||
Tumor stagee | ||||||
pT1-pT2 | 29 | 7 | 22 | 0.056 | -0.238 | |
pT3-pT4 | 36 | 22 | 19 | |||
Lymph node status | ||||||
Negative | 39 | 11 | 28 | 0.017 | -0.321 | |
Positive | 16 | 10 | 6 |
aOnly patients with primary bladder cancer were included; bcut-off: median immunoreactive score (IRS) according to Remmele and Stegner [23]; cFisher’s exact test; daccording to WHO 1973 classification according to WHO 2004 classification; eaccording to WHO 2004 classification; significant p-values are marked in bold face.